Lv21
148 积分 2023-09-07 加入
M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications
3小时前
待确认
Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation
3个月前
已完结
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
5个月前
已完结
Time-to-event Estimands in Oncology Trials: What’s Censoring Got To Do, Got To Do With It?
5个月前
已完结
Informative event rate in study determination, study design, and interim analysis monitoring with non-proportional hazards
5个月前
已完结
Causal interpretation of the hazard ratio in randomized clinical trials
6个月前
已完结
An adaptive imputation method of missing data for sparsely retrieved dropouts in treatment policy strategy
7个月前
已完结
Sensitivity analyses for the principal ignorability assumption using multiple imputation
7个月前
已完结
Invited Commentary: Why use methods that require proportional hazards?
9个月前
已完结
Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation
9个月前
已完结
皖公网安备34019202002308
